Utama › Kanser Gastrointestinal › Massachusetts › Boston
Kajian klinikal Kanser Gastrointestinal di Boston, MA
15 kajian untuk Kanser Gastrointestinal sedang mencari peserta di lokasi dalam dan sekitar Boston (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Mengambil pesertaFasa 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Mengambil pesertaFasa 3
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Mengambil pesertaFasa 3
- GSK Investigational Site, Boston
- GSK Investigational Site, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Mengambil pesertaFasa 1/2
- Dana Farber Cancer Institute, Boston
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Mengambil pesertaFasa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
Mengambil peserta
- Dana Farber Cancer Institute, Boston
Resilience and Equity in Aging, Cancer, and Health (REACH)
Mengambil peserta
- Dana-Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Mengambil pesertaFasa 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Mengambil pesertaFasa 1
- Dana-Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Massachusetts General Hospital Cancer Center, Boston
BOLSTER: Learning New Skills to Thrive
Mengambil peserta
- Dana-Farber Cancer Institute, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Mengambil pesertaFasa 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Mengambil pesertaFasa 1/2
- Massachusetts General Hospital,, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Mengambil pesertaFasa 1/2
- Dana Farber Cancer Institute, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Mengambil pesertaFasa 1/2
- Massachusetts General Hospital, Boston
Kajian Kanser Gastrointestinal di bandar lain
- Houston, TX21 kajian
- New York City, NY12 kajian
- Nashville, TN10 kajian
- Los Angeles, CA9 kajian
- Durham, NC8 kajian
- Dallas, TX8 kajian
- Baltimore, MD8 kajian
- Cincinnati, OH8 kajian
- Arlington, VA8 kajian
- San Antonio, TX7 kajian
- Baldwin Park, CA7 kajian
- Seattle, WA7 kajian
Kajian lain di Boston
- Kanser Payudara111 kajian
- Kanser Paru-paru Bukan Sel Kecil90 kajian
- Kanser (semua jenis)86 kajian
- Kanser Kolorektal63 kajian
- Kanser Metastatik63 kajian
- Kanser Paru-paru62 kajian
- Kanser Ovari61 kajian
- Kanser Prostat59 kajian
- Depresi52 kajian
- Kanser Endometrium50 kajian
- Kegagalan Jantung44 kajian
- Leukemia Mieloid Akut44 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.